Skyhawk Therapeutics entered a neurology-focused collaboration with Merck KGaA, potentially worth over $2 billion, targeting RNA splicing modulation for difficult-to-treat neurological diseases. Skyhawk's SkySTAR platform will discover small molecules aimed at RNA targets selected by Merck, with Merck controlling clinical development and commercialization. This builds on Skyhawk's phase 2/3 splicing modulator for Huntington’s disease and follows prior partnerships with major pharma including U.S. Merck & Co. The deal underscores growing confidence in RNA-targeted small-molecule therapies in neurology.